{"id":961807,"date":"2026-05-12T17:53:29","date_gmt":"2026-05-12T21:53:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/"},"modified":"2026-05-12T17:53:29","modified_gmt":"2026-05-12T21:53:29","slug":"tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/","title":{"rendered":"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May"},"content":{"rendered":"
\n

BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in May 2026.<\/p>\n

\n RBC Capital Markets Global Healthcare Conference<\/strong>
\n
\n Fireside Chat<\/strong>
\n
\n Participant:<\/strong> Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Location:<\/strong> New York, New York
Date:<\/strong> May 19, 2026
Time:<\/strong> 1:35 p.m. ET<\/p>\n

\n A.G.P.\u2019s Annual Virtual Healthcare Conference<\/strong>
\n
\n Fireside Chat<\/strong>
\n
\n Presenter:<\/strong> Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Location:<\/strong> Virtual
Date:<\/strong> May 20, 2026
Time:<\/strong> 3:00 p.m. ET<\/p>\n

Live webcasts and replays will be available under the News & Events tab in the Investors section of the Tonix website at https:\/\/ir.tonixpharma.com\/<\/a>.<\/p>\n

\n Tonix Pharmaceuticals Holding Corp.<\/strong>
\n
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA\u00ae<\/sup> (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix\u2019s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace\u00ae<\/sup> Symtouch\u00ae<\/sup> (sumatriptan injection 3 mg) and Tosymra\u00ae<\/sup> (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder\/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD154\/CD40 ligand (CD40L) inhibitor for the prevention of kidney transplant rejection. In addition, Tonix is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com<\/a>.<\/p>\n

\n *Tonix\u2019s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.<\/em>\n <\/p>\n

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.<\/p>\n

\n Forward Looking Statements
<\/strong>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimate,\u201d \u201cexpect,\u201d and \u201cintend,\u201d among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA\u00ae<\/sup> and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix\u2019s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.<\/p>\n

\n Investor Contacts
<\/strong>Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com<\/a>
(862) 799-8599<\/p>\n

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com<\/a><\/p>\n

\n Media Contacts
<\/strong>Deborah Elson
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com<\/a><\/p>\n

Ray Jordan
Putnam Insights
ray@putnaminsights.com<\/a>\u00a0\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in May 2026. RBC Capital Markets Global Healthcare Conference Fireside Chat Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: New York, New YorkDate: May 19, 2026Time: 1:35 p.m. ET A.G.P.\u2019s Annual Virtual Healthcare Conference Fireside Chat Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: VirtualDate: May 20, 2026Time: 3:00 p.m. ET Live webcasts and replays will be available under the News & Events tab in the Investors section of the Tonix website at https:\/\/ir.tonixpharma.com\/. … <\/p>\n

Continue reading “Tonix Pharmaceuticals to Participate in Two Investor Conferences in May”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-961807","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTonix Pharmaceuticals to Participate in Two Investor Conferences in May - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in May 2026. RBC Capital Markets Global Healthcare Conference Fireside Chat Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: New York, New YorkDate: May 19, 2026Time: 1:35 p.m. ET A.G.P.\u2019s Annual Virtual Healthcare Conference Fireside Chat Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: VirtualDate: May 20, 2026Time: 3:00 p.m. ET Live webcasts and replays will be available under the News & Events tab in the Investors section of the Tonix website at https:\/\/ir.tonixpharma.com\/. … Continue reading "Tonix Pharmaceuticals to Participate in Two Investor Conferences in May"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T21:53:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May\",\"datePublished\":\"2026-05-12T21:53:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/\"},\"wordCount\":701,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/\",\"name\":\"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=\",\"datePublished\":\"2026-05-12T21:53:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/","og_locale":"en_US","og_type":"article","og_title":"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in May 2026. RBC Capital Markets Global Healthcare Conference Fireside Chat Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: New York, New YorkDate: May 19, 2026Time: 1:35 p.m. ET A.G.P.\u2019s Annual Virtual Healthcare Conference Fireside Chat Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: VirtualDate: May 20, 2026Time: 3:00 p.m. ET Live webcasts and replays will be available under the News & Events tab in the Investors section of the Tonix website at https:\/\/ir.tonixpharma.com\/. … Continue reading \"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-12T21:53:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May","datePublished":"2026-05-12T21:53:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/"},"wordCount":701,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/","name":"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=","datePublished":"2026-05-12T21:53:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY3NSM3NTk4OTkyIzIwMTExMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tonix Pharmaceuticals to Participate in Two Investor Conferences in May"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=961807"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961807\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=961807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=961807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=961807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}